Carfilzomib for relapsed and refractory multiple myeloma

Area of Science:

• Hematology-Oncology
• Pharmacology
• Clinical Therapeutics

Background:

• Multiple myeloma (MM) prognosis has improved, yet relapsed refractory disease remains a challenge.
• Carfilzomib, a second-generation proteasome inhibitor (PI), is FDA-approved for relapsed/refractory MM.
• Carfilzomib demonstrates superior efficacy and reduced toxicity, particularly neuropathy, compared to bortezomib.

Purpose of the Study:

• To review clinical trial data supporting carfilzomib's approval for relapsed/refractory MM.
• To examine promising new combination studies involving carfilzomib.
• To provide prescribing guidance for physicians using carfilzomib.

Main Methods:

• Review of pivotal clinical trial data leading to carfilzomib's FDA approval.
• Analysis of ongoing and completed studies investigating carfilzomib combinations.
• Evaluation of carfilzomib's efficacy and safety profile, including comparisons with bortezomib.

Main Results:

• Carfilzomib shows superiority over bortezomib in efficacy and tolerability, with significantly less polyneuropathy.
• Cardiovascular adverse events are a notable toxicity concern with carfilzomib, requiring caution in specific patient populations.
• Once-weekly carfilzomib administration, approved in combination with dexamethasone, reduces patient and caregiver burden.

Conclusions:

• Carfilzomib is an effective treatment option for relapsed refractory multiple myeloma, offering advantages over first-generation PIs.
• Physicians must carefully weigh the benefits against the cardiovascular risks, especially in elderly or compromised patients.
• Emerging combinations and dosing strategies continue to refine carfilzomib's role in MM management.